- Independently developed and currently operating the sustained-release drug formulation platform ‘LLDDS’
- LLDDS dissolves polymers and semaglutide in an organic solvent and uses high-pressure spraying to produce microspheres sized 20–100 μm
- The entire process is carried out below 30℃, minimizing denaturation and enabling the production of peptide drugs, antibody drugs, and protein-based drugs
[The Bio – Reporter Kang In-hyo]
Tenpharma, a company specializing in the production of long-acting injectable drugs using polymer microsphere manufacturing technology, announced on the 16th that it has filed three domestic patent applications related to the production of polymer-based sustained-release drug formulations.
Tenpharma develops sustained-release drugs by creating polymer microspheres mixed with active pharmaceutical ingredients and administering them via subcutaneous injection. The company independently developed and currently operates a sustained-release drug formulation platform called LLDDS (Long Lasting Drug Delivery System).
The LLDDS platform dissolves polymers and semaglutide in an organic solvent and uses high-pressure spraying to produce microspheres ranging from 20 to 100 micrometers (μm) in size. According to the company, the entire process is conducted at temperatures below 30℃, which minimizes denaturation and allows for the production of peptide drugs, antibody drugs, and protein-based drugs. Additionally, various synthetic pharmaceuticals can be encapsulated within the polymer microspheres.
Ro Young-woo, CEO of Tenpharma, stated, “The sustained-release drugs under development can be designed to maintain efficacy for periods ranging from one month to over a year, potentially offering a new alternative in the market,” adding, “We are currently developing sustained-release formulations for eight major drug substances.”
- Independently developed and currently operating the sustained-release drug formulation platform ‘LLDDS’
- LLDDS dissolves polymers and semaglutide in an organic solvent and uses high-pressure spraying to produce microspheres sized 20–100 μm
- The entire process is carried out below 30℃, minimizing denaturation and enabling the production of peptide drugs, antibody drugs, and protein-based drugs
[The Bio – Reporter Kang In-hyo]
Tenpharma, a company specializing in the production of long-acting injectable drugs using polymer microsphere manufacturing technology, announced on the 16th that it has filed three domestic patent applications related to the production of polymer-based sustained-release drug formulations.
Tenpharma develops sustained-release drugs by creating polymer microspheres mixed with active pharmaceutical ingredients and administering them via subcutaneous injection. The company independently developed and currently operates a sustained-release drug formulation platform called LLDDS (Long Lasting Drug Delivery System).
The LLDDS platform dissolves polymers and semaglutide in an organic solvent and uses high-pressure spraying to produce microspheres ranging from 20 to 100 micrometers (μm) in size. According to the company, the entire process is conducted at temperatures below 30℃, which minimizes denaturation and allows for the production of peptide drugs, antibody drugs, and protein-based drugs. Additionally, various synthetic pharmaceuticals can be encapsulated within the polymer microspheres.
Ro Young-woo, CEO of Tenpharma, stated, “The sustained-release drugs under development can be designed to maintain efficacy for periods ranging from one month to over a year, potentially offering a new alternative in the market,” adding, “We are currently developing sustained-release formulations for eight major drug substances.”